Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,93
KB-0,72
PKN130,5130,9-0,38
Msft-0,08
IBM-0,20
DCX68,8668,870,50
PFE0,61
18.10.2017 1:38:28
Indexy online
AD Index online
select
AD Index online
 

  • 17.10.2017 22:00:00
ADMA Biologics (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
2,93 -1,35 -0,04 26 316
After-hours17.10.2017 23:20:00
Poslední obchod Nákup / Prodej Změna (%) Změna (USD)
2,93 - - -1,35 -0,04
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 18.10.2017
Popis společnosti
Obecné informace
Název společnostiADMA Biologics Inc
TickerADMA
Kmenové akcie:Ordinary Shares
RICADMA.O
ISINUS0008991046
Prioritní akciePreferred Shares
Poslední známé roční výsledky31.12.2016
Poslední známé čtvrtletní výsledky30.6.2017
Počet zaměstnanců k 31.12.2016 92
Akcie v oběhu k 11.8.2017 25 793 404
MěnaUSD
Kontaktní informace
UliceC/O Adma Biologics
MěstoRAMSEY
PSČ07446
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon12 014 785 552
Fax12014785553

Business Summary: ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.
Financial Summary: BRIEF: For the six months ended 30 June 2017, ADMA Biologics Inc revenues increased 37% to $6M. Net loss increased 47% to $15.6M. Revenues reflect Plasma Collection Center segment increase of 25% to $5.4M. Higher net loss reflects Corporate segment loss increase from $3.8M to $8.9M, Plasma Collection Center segment loss increase of 29% to $1.1M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.93 to -$1.06.
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSBiological Product (except Diagnostic) Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
SICBiological Prod's Not Diagnostic
SICBiological Prod's Not Diagnostic
SICCommercial Physical Research



  • Poslední aktualizace: 18.10.2017
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the BoardSteven Elms53
President, Chief Executive Officer, DirectorAdam Grossman381.1.2007
Vice Chairman of the BoardJerrold Grossman67
Chief Financial OfficerBrian Lenz431.5.20121.5.2012
Chief Scientific and Medical OfficerJames Mond6918.7.201218.7.2012